🎗️ ECS Academy · Oncology Handbook

Cannabinoid evidence in oncology and supportive care

An oncologist-facing clinical handbook for supportive-care evidence, ECS modulation mechanisms and conservative clinical boundaries in medical cannabis research.

71Source-linked cards
33PMID entries
29PMCID entries
8Trusted domains
Open the evidence browser Clinical guardrails
Evidence map

Oncology evidence lenses

Designed for oncologists: guidance, supportive-care symptom evidence, and preclinical mechanism rows are separated logically.

Evidence browser

Oncologist evidence browser

Filter by oncology lens, indication, evidence tier or keyword. Each card keeps conservative clinical wording and primary source links.

71 visible71 total source-linked cards
Research ContextGuideline / official boundaryncbi.nlm.nih.gov

Cannabinoid Antiemetic Therapy — StatPearls (2025)

Guidelines & boundaries · Supportive Oncology — CINV · Dronabinol, nabilone

Validated — Guideline/official boundary source
Clinical wording: “Do not use cannabis/cannabinoids as cancer-directed treatment outside a clinical trial.”
DOI/ID: NBK535430Source ID: RES-0082
Open source ↗
Clinical GuidelineGuideline / official boundaryascopubs.org

ASCO Guideline (2024)

Guidelines & boundaries · Cancer — General / Pan-Cancer

Validated — Guideline/official boundary source
Clinical wording: “Do not use cannabis/cannabinoids as cancer-directed treatment outside a clinical trial.”
DOI/ID: 10.1200/JCO.23.02596Source ID: RES-0001
Open source ↗
Clinical GuidelineGuideline / official boundaryncbi.nlm.nih.gov

Cancer — Health Effects of Cannabis and Cannabinoids (2017)

Guidelines & boundaries · Cancer — General / Pan-Cancer · Cannabis, cannabinoids

Validated — Guideline/official boundary source
Clinical wording: “Do not use cannabis/cannabinoids as cancer-directed treatment outside a clinical trial.”
DOI/ID: NBK425761Source ID: RES-0088
Open source ↗
Research ContextGuideline / official boundaryncbi.nlm.nih.gov

Therapeutic Effects of Cannabis and Cannabinoids — NCBI Bookshelf (2017)

Guidelines & boundaries · Supportive Oncology — Pain · Cannabis, cannabinoids

Validated — Guideline/official boundary source
Clinical wording: “Cannabinoid antiemetic evidence is mainly adjunct/salvage supportive care under oncology supervision.”
DOI/ID: NBK425767Source ID: RES-0093
Open source ↗
Clinical GuidelineGuideline / official boundaryncbi.nlm.nih.gov

Cannabis and Cannabinoids (PDQ®) — NCI/NCBI (Updated)

Guidelines & boundaries · Cancer — General / Pan-Cancer · Cannabis, cannabinoids, CBD, THC

Validated — Guideline/official boundary source
Clinical wording: “May be discussed as supportive oncology symptom-care evidence, not cancer treatment.”
DOI/ID: NBK65875Source ID: RES-0085
Open source ↗
Research ContextGuideline / official boundarycancer.gov

NCI PDQ (Updated 2025)

Guidelines & boundaries · Cancer — General / Pan-Cancer

Validated — Guideline/official boundary source
Clinical wording: “May be discussed as supportive oncology symptom-care evidence, not cancer treatment.”
Source ID: RES-0055
Open source ↗
Research ContextScientific sourcepubmed.ncbi.nlm.nih.gov

CBD Anti-Metastatic Activity in Breast Cancer — Id-1 Gene Suppression (2007)

Anti-proliferative mechanisms · Cancer — Breast · CBD

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 17938263Source ID: RES-0002
Open source ↗
Research ContextClinical synthesispmc.ncbi.nlm.nih.gov

CBD efficacy in chronic neuropathic pain: systematic review

Supportive-care symptoms · Supportive Oncology — Pain

Validated — Scientific source; claim must match endpoint and population
Clinical wording: “Use as evidence-informed ECS/cannabinoid research navigation; avoid product-specific disease claims.”
PMCID: PMC7281088Source ID: RES-0095
Open source ↗
Research ContextPreclinical / mechanisticpubmed.ncbi.nlm.nih.gov

CBD inhibits lung cancer invasion and metastasis

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 20331200Source ID: RES-0021
Open source ↗
Research ContextHuman clinical evidencepmc.ncbi.nlm.nih.gov

Mechanisms of Cannabidiol (CBD) in Cancer Treatment (2022)

Supportive-care symptoms · Cancer — General / Pan-Cancer · CBD

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “May be discussed as supportive oncology symptom-care evidence, not cancer treatment.”
PMCID: PMC9220307Source ID: RES-0081
Open source ↗
Research ContextHuman clinical evidencepmc.ncbi.nlm.nih.gov

CBD as a Potential Anti-Cancer Agent: Review of Clinical Trials (2020)

Human clinical / synthesis · Cancer — General / Pan-Cancer · CBD

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMCID: PMC7546571Source ID: RES-0005
Open source ↗
Research ContextPreclinical / mechanisticpubmed.ncbi.nlm.nih.gov

CBD as an Inducer of Apoptosis in Human Glioma Cells (2014)

Glioma / brain tumor research · Cancer — Glioma / Brain · CBD

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 24373545Source ID: RES-0089
Open source ↗
Research ContextPreclinical / mechanisticpmc.ncbi.nlm.nih.gov

Cannabidiol-Induced Apoptosis in Human Leukemia Cells (2013)

Human clinical / synthesis · Cancer — General / Pan-Cancer · CBD

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMCID: PMC3579246Source ID: RES-0029
Open source ↗
Research ContextPreclinical / mechanisticpubmed.ncbi.nlm.nih.gov

Cannabidiol Promotes Apoptosis in Human Breast Cancer Cells via CB2 (2011)

Human clinical / synthesis · Cancer — Breast · CBD

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 21566064Source ID: RES-0024
Open source ↗
Research ContextHuman clinical evidencepubmed.ncbi.nlm.nih.gov

Endometrial Cancer Apoptosis

Human clinical / synthesis · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 29441458Source ID: RES-0068
Open source ↗
Verified SourcePeer-reviewed reviewpubmed.ncbi.nlm.nih.gov

Anti-Cancer and Anti-Proliferative Potential of Cannabidiol: A Cellular and Molecular Perspective (2024)

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer · CBD

Validated — peer-reviewed PubMed/PMC review; oncology claim must remain preclinical/mechanistic unless human endpoint exists.
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 38891847PMCID: PMC11171526DOI/ID: 10.3390/ijms25115659Source ID: RES-0091
Open source ↗
Verified SourcePeer-reviewed reviewpubmed.ncbi.nlm.nih.gov

Endocannabinoid signaling in glioma (2023)

Glioma / brain tumor research · Cancer — Glioma / Brain · THC, CBD

Validated — glioma-specific peer-reviewed source; use only for mechanistic research navigation, not therapeutic efficacy claims.
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 35322459PMCID: PMC9790654DOI/ID: 10.1002/1878-0261.13250Source ID: RES-0090
Open source ↗
Verified SourceScientific sourcepubmed.ncbi.nlm.nih.gov

Entourage Effect

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Validated — Scientific source; claim must match endpoint and population
Clinical wording: “May be discussed as supportive oncology symptom-care evidence, not cancer treatment.”
PMID: 21749363Source ID: RES-0047
Open source ↗
Verified SourceScientific sourcepubmed.ncbi.nlm.nih.gov

Strengths and Limits of Cannabinoids

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Validated — Scientific source; claim must match endpoint and population
Clinical wording: “May be discussed as supportive oncology symptom-care evidence, not cancer treatment.”
PMID: 34624678Source ID: RES-0070
Open source ↗
Research ContextPeer-reviewed reviewpmc.ncbi.nlm.nih.gov

Cannabinoids in Chronic Pain Management: A Review of the Evidence (2025)

Supportive-care symptoms · Supportive Oncology — Pain · THC, CBD, cannabinoids

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “May be discussed as supportive oncology symptom-care evidence, not cancer treatment.”
PMCID: PMC11940634Source ID: RES-0094
Open source ↗
Research ContextPeer-reviewed reviewpubmed.ncbi.nlm.nih.gov

Pharmacological effects of cannabidiol by transient receptor potential channels (2022)

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer · CBD, TRPV1/TRP channels

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “May be discussed as supportive oncology symptom-care evidence, not cancer treatment.”
PMID: 35483477Source ID: RES-0078
Open source ↗
Research ContextPeer-reviewed reviewpmc.ncbi.nlm.nih.gov

Opportunities for cannabis in supportive care in cancer (2019)

Supportive-care symptoms · Cancer — General / Pan-Cancer · Cannabis, cannabinoids

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoid antiemetic evidence is mainly adjunct/salvage supportive care under oncology supervision.”
PMCID: PMC6676264Source ID: RES-0084
Open source ↗
Research ContextPeer-reviewed reviewpmc.ncbi.nlm.nih.gov

Cannabinoids for treating inflammatory bowel diseases (2017)

Supportive-care symptoms · Cancer — General / Pan-Cancer · Cannabinoids

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “May be discussed as supportive oncology symptom-care evidence, not cancer treatment.”
PMCID: PMC5388177Source ID: RES-0086
Open source ↗
Research ContextPeer-reviewed reviewpmc.ncbi.nlm.nih.gov

Therapeutic Use of Cannabis in Inflammatory Bowel Disease (2016)

Supportive-care symptoms · Cancer — General / Pan-Cancer · Cannabis, ECS

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “May be discussed as supportive oncology symptom-care evidence, not cancer treatment.”
PMCID: PMC5193087Source ID: RES-0087
Open source ↗
Research ContextPeer-reviewed reviewpubmed.ncbi.nlm.nih.gov

Cannabinoids in treating chemotherapy-induced nausea and vomiting (2012)

CINV / nausea · Supportive Oncology — CINV · Dronabinol, nabilone, cannabinoids

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoid antiemetic evidence is mainly adjunct/salvage supportive care under oncology supervision.”
PMID: 22491047Source ID: RES-0083
Open source ↗
Research ContextPeer-reviewed reviewpmc.ncbi.nlm.nih.gov

Clinical Data Review

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “May be discussed as supportive oncology symptom-care evidence, not cancer treatment.”
PMCID: PMC8864433Source ID: RES-0059
Open source ↗
Research ContextPeer-reviewed reviewpmc.ncbi.nlm.nih.gov

ECS Review

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “May be discussed as supportive oncology symptom-care evidence, not cancer treatment.”
PMCID: PMC5877694Source ID: RES-0044
Open source ↗
Research ContextPeer-reviewed reviewpmc.ncbi.nlm.nih.gov

Inflammation Review

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “May be discussed as supportive oncology symptom-care evidence, not cancer treatment.”
PMCID: PMC2828614Source ID: RES-0054
Open source ↗
Research ContextPeer-reviewed reviewnature.com

Nature Reviews Cancer

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
Source ID: RES-0056
Open source ↗
Research ContextPreclinical / mechanisticmdpi.com

Mechanisms of Cannabidiol in Cancer Treatment: Mitochondrial Apoptosis (2022)

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer · CBD

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
Source ID: RES-0025
Open source ↗
Research ContextPreclinical / mechanisticpmc.ncbi.nlm.nih.gov

Antitumor Effects of Cannabidiol in Preclinical Glioma Models (2020)

Glioma / brain tumor research · Cancer — General / Pan-Cancer · CBD

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMCID: PMC7572340Source ID: RES-0009
Open source ↗
Research ContextPreclinical / mechanisticpubmed.ncbi.nlm.nih.gov

Kaempferol: Anti-cancer Flavonoid Synergy with CBD — PPARγ and Apoptosis (2018)

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer · Kaempferol, CBD

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 29161914Source ID: RES-0048
Open source ↗
Research ContextPreclinical / mechanisticpubmed.ncbi.nlm.nih.gov

CBD + Temozolomide: Synergistic Apoptosis in Glioblastoma (2013)

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer · CBD, THC

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 23918706Source ID: RES-0028
Open source ↗
Research ContextPreclinical / mechanisticpubmed.ncbi.nlm.nih.gov

THCA as Anti-proliferative Agent in Prostate Cancer — Non-psychoactive (2012)

Anti-proliferative mechanisms · Cancer — Prostate · THCA

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 24237856Source ID: RES-0012
Open source ↗
Research ContextPreclinical / mechanisticpubmed.ncbi.nlm.nih.gov

Antitumorigenic Effects Beyond Apoptosis

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 19889794Source ID: RES-0062
Open source ↗
Research ContextPreclinical / mechanisticpmc.ncbi.nlm.nih.gov

Apoptosis Research

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMCID: PMC4367590Source ID: RES-0030
Open source ↗
Research ContextPreclinical / mechanisticpubmed.ncbi.nlm.nih.gov

CBD Lung Cancer Cell Apoptosis

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 23220503Source ID: RES-0063
Open source ↗
Research ContextPreclinical / mechanisticpubmed.ncbi.nlm.nih.gov

CBD induces apoptosis in leukemia via CB2

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 16908594Source ID: RES-0020
Open source ↗
Research ContextPreclinical / mechanisticpubmed.ncbi.nlm.nih.gov

CBG anti-proliferative in colon cancer via TRPM8

Anti-proliferative mechanisms · Cancer — Colorectal / Colon

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 24590129Source ID: RES-0019
Open source ↗
Research ContextPreclinical / mechanisticpubmed.ncbi.nlm.nih.gov

Cellular Proliferation Regulation

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 15638794Source ID: RES-0065
Open source ↗
Research ContextPreclinical / mechanisticpubmed.ncbi.nlm.nih.gov

Ceramide-Mediated Apoptosis

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 11903061Source ID: RES-0066
Open source ↗
Research ContextPreclinical / mechanisticpubmed.ncbi.nlm.nih.gov

Pancreatic Tumor Cell Apoptosis

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 16818650Source ID: RES-0069
Open source ↗
Research ContextScientific sourcepmc.ncbi.nlm.nih.gov

Cannabidiol on the Path from the Lab to the Cancer Patient (2022)

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer · CBD

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMCID: PMC8951434Source ID: RES-0008
Open source ↗
Research ContextScientific sourcemdpi.com

The Role of Cannabinoids in Inflammation and Cancer (2021)

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer · THC, CBD

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
Source ID: RES-0026
Open source ↗
Research ContextScientific sourcepmc.ncbi.nlm.nih.gov

Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids in Cannabis (2020)

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer · CBD, THC, Full Spectrum

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMCID: PMC7409346Source ID: RES-0004
Open source ↗
Research ContextScientific sourcepmc.ncbi.nlm.nih.gov

CBD in Oncology: Current and Future Perspectives (2020)

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer · CBD

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMCID: PMC7511370Source ID: RES-0006
Open source ↗
Research ContextScientific sourcepmc.ncbi.nlm.nih.gov

CBD: A Killer for Inflammatory Rheumatoid Arthritis Synovial Fibroblasts (2020)

Supportive-care symptoms · Cancer — General / Pan-Cancer · CBD

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “May be discussed as supportive oncology symptom-care evidence, not cancer treatment.”
PMID: 32873774PMCID: PMC7463000DOI/ID: 10.1038/s41419-020-02892-1Source ID: RES-0097
Open source ↗
Research ContextScientific sourcepmc.ncbi.nlm.nih.gov

Cannabidiol and Cancer: Therapeutic Potentials and Challenges (2020)

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer · CBD

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMCID: PMC7456558Source ID: RES-0007
Open source ↗
Research ContextScientific sourcemdpi.com

Cannabinoids and Cancer: Therapeutic Possibilities (2020)

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer · THC, CBD

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
Source ID: RES-0092
Open source ↗
Research ContextScientific sourcepmc.ncbi.nlm.nih.gov

Synergistic Effects of CBD and Chemotherapy in Cancer Treatment (2020)

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer · CBD

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMCID: PMC7525662Source ID: RES-0027
Open source ↗
Research ContextScientific sourcepmc.ncbi.nlm.nih.gov

Cannabinoids as Potential Anticancer Agents — THC/CBD via CB1/CB2 (2015)

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer · THC, CBD

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMCID: PMC4791144Source ID: RES-0010
Open source ↗
Research ContextScientific sourcepubmed.ncbi.nlm.nih.gov

CBG as Antiproliferative Agent in Colorectal Cancer via TRPM8 (2013)

Anti-proliferative mechanisms · Cancer — Colorectal / Colon · CBG

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 24675530Source ID: RES-0003
Open source ↗
Research ContextScientific sourcepmc.ncbi.nlm.nih.gov

Cannabinoid Receptor 2: Role in Immunomodulation and Neuroinflammation (2013)

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer · CBD

Validated — Scientific source; claim must match endpoint and population
Clinical wording: “May be discussed as supportive oncology symptom-care evidence, not cancer treatment.”
PMCID: PMC3662320Source ID: RES-0053
Open source ↗
Research ContextScientific sourcepubmed.ncbi.nlm.nih.gov

CBD Androgen Receptor Suppression in Prostate Cancer (2012)

Anti-proliferative mechanisms · Cancer — Prostate · CBD

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 23095328Source ID: RES-0011
Open source ↗
Research ContextScientific sourcepubmed.ncbi.nlm.nih.gov

Anti-cancer potential: cannabinoids, terpenes, flavonoids

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 32804395Source ID: RES-0016
Open source ↗
Research ContextScientific sourcepubmed.ncbi.nlm.nih.gov

Anticancer Mechanisms of Cannabinoids

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 27022311Source ID: RES-0061
Open source ↗
Research ContextScientific sourcepubmed.ncbi.nlm.nih.gov

CBD for Chemotherapy-Induced Peripheral Neuropathy

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer · CBD

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “May be discussed as supportive oncology symptom-care evidence, not cancer treatment.”
PMID: 38343646Source ID: RES-0058
Open source ↗
Research ContextScientific sourcepubmed.ncbi.nlm.nih.gov

CBD reduces prostate cancer via androgen receptor

Anti-proliferative mechanisms · Cancer — Prostate

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 18789600Source ID: RES-0022
Open source ↗
Research ContextScientific sourcepmc.ncbi.nlm.nih.gov

CBD synergistic with chemo: enhanced efficacy

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMCID: PMC5022434Source ID: RES-0017
Open source ↗
Research ContextScientific sourcepmc.ncbi.nlm.nih.gov

CBD: lab to cancer patient - multiple cancers

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMCID: PMC6387667Source ID: RES-0018
Open source ↗
Research ContextScientific sourcepmc.ncbi.nlm.nih.gov

Cancer Pain

Supportive-care symptoms · Supportive Oncology — Pain

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “May be discussed as supportive oncology symptom-care evidence, not cancer treatment.”
PMCID: PMC2503660Source ID: RES-0035
Open source ↗
Research ContextScientific sourcepubmed.ncbi.nlm.nih.gov

Cannabinoid Signaling in Cancer

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 31332734Source ID: RES-0064
Open source ↗
Research ContextScientific sourcepubmed.ncbi.nlm.nih.gov

Cannabinoids in Supportive Cancer Care: Cachexia, Appetite and Weight Restoration

Supportive-care symptoms · Cancer — General / Pan-Cancer · CBD, THC

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “May be discussed as supportive oncology symptom-care evidence, not cancer treatment.”
PMID: 37476324Source ID: RES-0077
Open source ↗
Research ContextScientific sourcepubmed.ncbi.nlm.nih.gov

ECS in Cancer Biology

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 29663308Source ID: RES-0067
Open source ↗
Research ContextScientific sourcepubmed.ncbi.nlm.nih.gov

Formulation evidence: Cannoflam DS — Full Spectrum Extract

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer · CBD + THC 1:1 ratio + terpenes

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 29322089Source ID: RES-0079
Open source ↗
Research ContextScientific sourcepubmed.ncbi.nlm.nih.gov

Formulation evidence: Prolifex (Prana) — CBD + THC Synergy

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer · CBD + THC + terpenes

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMID: 32234203Source ID: RES-0080
Open source ↗
Research ContextScientific sourcenature.com

Full-Spectrum Cannabis Superior to Isolate: Entourage Anti-Cancer Effect

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer · Full Spectrum

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
Source ID: RES-0046
Open source ↗
Research ContextScientific sourcepmc.ncbi.nlm.nih.gov

Full-spectrum cannabis for post-cancer pain

Supportive-care symptoms · Supportive Oncology — Pain

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “May be discussed as supportive oncology symptom-care evidence, not cancer treatment.”
PMCID: PMC5669217Source ID: RES-0096
Open source ↗
Research ContextScientific sourcepmc.ncbi.nlm.nih.gov

Head & Neck Cancer Supportive Care

Anti-proliferative mechanisms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMCID: PMC12764220Source ID: RES-0060
Open source ↗
Research ContextScientific sourcebmj.com

Medical Cannabis for Cancer Pain

Supportive-care symptoms · Supportive Oncology — Pain

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “May be discussed as supportive oncology symptom-care evidence, not cancer treatment.”
Source ID: RES-0032
Open source ↗
Research ContextScientific sourcepmc.ncbi.nlm.nih.gov

QOL Oncology

Supportive-care symptoms · Cancer — General / Pan-Cancer

Research context — Preclinical oncology/mechanistic; do not claim cancer treatment efficacy
Clinical wording: “Cannabinoids have preclinical/mechanistic oncology signals; human anti-cancer efficacy is not established.”
PMCID: PMC9020711Source ID: RES-0071
Open source ↗
Use boundaries

Scientific and logical use boundaries

This physician-facing handbook keeps the evidence useful without overstating indication claims or treatment efficacy.

Supportive-care framing

Use for evidence navigation around pain, nausea/CINV, appetite/cachexia, sleep, QOL and ECS education under clinician supervision.

Preclinical oncology boundary

Anti-proliferative, apoptosis and radiosensitization rows are research mechanisms unless a human clinical endpoint is shown.

Patient safety screen

Screen sedation, psychiatric risk, pregnancy, liver disease, anticoagulants, CYP/P-gp interactions, immunotherapy context and active oncology protocols.

Citation

How to cite this handbook

Citing this handbook — or exporting its full reference library — helps other clinicians and researchers find it. Copy a ready-made citation, or export all 71 source-linked references for Zotero, Mendeley or EndNote.

APA

EndoCann. (2026). Cannabinoid evidence in oncology and supportive care. Retrieved , from https://endocann.in/ECS/oncology/

Vancouver / ICMJE

EndoCann. Cannabinoid evidence in oncology and supportive care [Internet]. India: EndoCann; 2026 [cited ]. Available from: https://endocann.in/ECS/oncology/

BibTeX

@misc{endocann_oncology_2026, title = {Cannabinoid evidence in oncology and supportive care}, author = {{EndoCann}}, year = {2026}, howpublished = {\url{https://endocann.in/ECS/oncology/}}, note = {Accessed } }
Educational use only. This library supports evidence navigation by qualified professionals and does not replace independent medical judgement, product labelling or local regulation. See our legal & medical disclaimer and editorial policy.

Related resources